Curis (NASDAQ:CRIS) Posts Earnings Results, Beats Expectations By $0.14 EPS

Curis (NASDAQ:CRIS) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($1.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.39) by $0.14, RTT News reports. Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%. During the same period in the prior year, the company earned ($2.05) earnings per share.

Curis Price Performance

NASDAQ CRIS traded down $0.17 during trading hours on Tuesday, hitting $2.29. 95,537 shares of the company’s stock traded hands, compared to its average volume of 67,434. Curis has a 52-week low of $1.02 and a 52-week high of $16.93. The company has a market capitalization of $19.40 million, a PE ratio of -0.29 and a beta of 3.65. The firm’s 50-day moving average is $2.07 and its 200-day moving average is $3.14.

Analyst Ratings Changes

Several analysts have commented on the company. StockNews.com initiated coverage on Curis in a report on Wednesday, April 30th. They issued a “hold” rating on the stock. HC Wainwright cut their price target on shares of Curis from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday, March 31st.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.